

86894\_Auto\_Edited.docx

---

WORD COUNT

8087

TIME SUBMITTED

22-AUG-2023 04:23PM

PAPER ID

102162763

## Reasons and effects of the decline of willing related potential living kidney donors

Gadelkareem RA *et al.* Declined willing related living kidney donors

3

Rabea Ahmed Gadelkareem, Amr Mostafa Abdelgawad, Nasreldin Mohammed, Ahmed Reda, Nashwa Mostafa Azoz, Mohammed Ali Zarzour, Hisham Mokhtar Hammouda, Mahmoud Khalil

### Abstract

#### BACKGROUND

Although the availability of related living donors (LDs) provides great chances for receiving kidney transplantation (KT), the evaluation protocols for LD selection remain a safeguard for the LD's safety. These protocols are variable from one center to another, resulting in variable rates of decline of the potential LDs (PLDs). The decline of willing PLDs may occur at any stage of evaluation, starting from the initial contact and counseling to the day of operation.

#### AIM

To identify the causes of the decline of PLDs, the predictors of PLD candidacy, and the effect on achieving LDKT.

#### METHODS

A retrospective study was performed on the willing PLDs who attended our outpatient clinic for kidney donation to their related potential recipients between October 2015 and December 2022. The variables influencing their candidacy rate and the fate of their potential recipients were studied. Two groups of PLDs were compared: Candidate PLDs after a completed evaluation *vs* non-candidate PLDs with a complete or incomplete evaluation. A multivariate logistic regression was performed to assess the factors contributing to the achievement of PLD candidacy.

## RESULTS

Of 321 willing PLDs, 257 (80.1%) PLDs accessed the evaluation to variable extents for 212 potential recipients, with a mean age (range) of  $40.5 \pm 10.4$  (18-65) years, including 169 (65.8%) women. The remaining 64 (19.9%) PLDs did not access the evaluation. Only 58 (18.1%) PLDs succeeded in donating, but 199 (62.0%) were declined; exclusion occurred in 144 (56.0%) PLDs for immunological (37.5%), medical (60.4%), and financial (2.1%) causes; regression and release occurred in 55 (17.1%) PLDs. The potential recipients with candidate PLDs were not significantly different from those with non-candidate PLDs, except in age ( $P = 0.041$ ), rates of completed evaluation, and exclusion of PLDs ( $P < 0.001$ ). There were no factors that independently influenced the rate of PLD candidacy. Most patients who failed to have KT after the decline of their PLDs remained on hemodialysis for 6 months to 6 years.

## CONCLUSION

The rate of decline of willing related PLDs was high due to medical or immunological contraindications, release, or regression of PLDs. It reduced the chances of high percentages of potential recipients in LDKT.

**Key Words:** Donor decline; Donor evaluation; Donor exclusion; Kidney transplantation; Living kidney donors; Related living donors

<sup>3</sup> Gadelkareem RA, Abdelgawad AM, Mohammed N, Reda A, Azoz NM, Zarzour MA, Hammouda HM, Khalil M. Reasons and effects of the decline of willing related potential living kidney donors. *World J Transplant* 2023; In press

**Core Tip:** The rate of decline of willing related potential living kidney donors (PLDs) was high (82%). The causes of decline included exclusion by the transplant team due to contraindications of donation, release after disqualification of the potential recipients,

and regression due to withdrawal of the decision by the PLDs. PLD exclusion was the commonest form of decline due to medical or immunological contraindications. The high rate of PLD decline resulted in the loss of chances of kidney transplantation for high percentages of potential recipients who were left on dialysis for variably long periods, died, or were lost to an unknown fate.

## **INTRODUCTION**

Living donor kidney transplantation (LDKT) is the optimal form of renal replacement therapy. It shortens the waiting times and provides better survival rates. Hence, it is recommended as the first choice treatment for each candidate patient with end-stage renal disease (ESRD), especially with the availability of related potential LDs (PLDs)<sup>[1,2]</sup>. However, it is not easy to find a willing, suitable LD. In addition, the preparation of a potential donor-recipient pair for KT is practically a complex sequential process<sup>[3,4]</sup>. Relative to the variability of assessment protocols, the reported acceptance rate of LDs is variable at 8.0%-18.4%<sup>[4,5]</sup>. This variability in acceptance of LDs is significant among countries, medical societies, health organizations, and KT units<sup>[3,6]</sup>. A large proportion of those PLDs may initially be declined for demographic issues, such as unsuitable age and genetical unrelatedness, or excluded later on during preparation due to different medical reasons<sup>[5,7,8]</sup>. Although the exclusion of a willing potential LD may negatively reflect on the potential recipients by reducing their chances of transplantation, it is still a paramount principle not to violate the donor's safety for the recipient's benefit<sup>[3-5]</sup>. In our center, the maintenance of this narrow-margin principle between the donor's safety and the recipient's benefit through the assessment process was the motivator for the conduct of the current study. The aim was to assess the reasons for the decline of PLDs and their effects on the fate of potential recipients.

## **MATERIALS AND METHODS**

### ***Study design***

A retrospective study was carried out by reviewing the data of the PLDs of ESRD patients who presented to our center seeking KT from October 2015 to December 2022. The inclusion criteria were a related PLD presented to our center for donation to a related, intended patient with ESRD. Exclusion criteria included an initial failure to confirm the willingness to donate a kidney (Figure 1).

### *The flow of PLDs evaluation*

In our policy, the process of PLD evaluation could be differentiated into six phases, from the initial contact to the achievement of a donation (Figure 2). Owing to the unavailability of a national waitlisting program and the nature of related living kidney donation (LKD), PLDs are directly presented with their intended recipients at the KT center. The initial two phases consist of contact with the KT center, confirmation of willingness to donate a kidney to an intended related potential recipient, counseling about KT, sociodemographic evaluation (age and financial issues), and blood group matching. History-taking is usually performed at the first contact or counseling session, excluding previously known systemic diseases, financial issues, and factors violating the integrity of volunteer donation. The third and fourth phases are multidisciplinary steps, including medical and immunological evaluations.

The medical evaluation consists of physical examinations, laboratory workups, and imaging workups. Kidney function was evaluated using the Technetium 99 Diethylenetriamine Pentaacetate ( $^{99m}\text{Tc}$  DTPA) renography for measurement of the total and split glomerular filtration rates in all PLDs. However, the anatomical features were evaluated by abdominal ultrasonography and contrast-enhanced computed tomography with renal angiography. Psychosocial assessment was a routine workup to evaluate the mental status of the PLDs, motives for donation, cognitive capacity, expectations after donation, and exclude any psychogenic drive for self-harm. In addition, evaluation and exclusion of drug addiction was performed.

The immunological workups include crossmatching, human leukocytic antigen (HLA) typing, and panel reactive antibody tests. The fifth phase includes medicolegal

permissions, determination of the date of surgery, and revision of the important tests. The sixth phase is the donation achievement.

### ***Study outcomes and variables***

The primary outcome of this study was the candidacy rate of PLDs. It was defined as the percentage of PLDs with complete preparation for LKD and acceptance for donation, either when the transplantation was performed or it was cancelled due to causes related to the patient. Because the relevant characteristics of the intended patients were significant for the identification of the causes of decline of PLDs and their fates, relevant characteristics of those intended patients and their distribution per the outcomes of evaluation of their PLDs. Each patient's file was examined for relevant demographic and clinical characteristics and related PLDs. The studied characteristics included the number, age, relatedness form and degree, decline form (exclusion, release, or regression), and causes of the decline of PLDs. In addition, the fate of PLDs and patients with declined PLDs was studied. Here, the relatedness was presented relative to the genetic relatedness degrees (ABO-relatedness).

According to the primary outcome, the PLDs were differentiated into two groups. The first group was the candidate donors, including the finally accepted donors with a completed evaluation and preparation for donation. The second group was the non-candidate donors, including the remaining donors who were disqualified as PLDs, either with or without initial acceptance or a completed evaluation. The characteristics of both groups were compared with each other. The secondary outcomes were the rate of PLD decline in each phase of evaluation and the fate of patients with declined PLDs.

### ***Sociodemographic definitions and documentation of donor-recipient relatedness***

Throughout the process of LKD, the different statuses of the PLD were distinguished from each other as well-defined clinical events. They were defined to describe the events of PLD evaluation, from access to the achievement of LKD (Table 1). Based on these definitions, the outcomes of the study were estimated.

Official documents from the Civil Registry Office were requested to document the degree of genetic relatedness between the PLD and the intended recipient. Routinely, the birth certificates and national identity numbers for all PLDs and their intended recipients were the basic documents for all PLDs. In our center, the first and second degrees of genetic relatedness of PLDs were routinely allowed, based on these routine documents. If there was difficulty finding a PLD, the third and fourth degrees were allowed after investigations, and they were mostly processed similarly to the unrelated PLDs. In the latter instances, further documentation was warranted, such as a family genealogy tree from the Civil Registry Office and consent registered in the Real Estate Publicity Department and Documentation Office.

#### *The processes employed to investigate the transparency of kidney donation*

The transparency of the donation as an unpaid act was verified via multiple processes to identify and exclude any financial agreements in these cases: (1) Direct confrontation of the PLD and intended recipient with this issue during counseling and warning them that KT would not be done if there was any violation to moral donation principle; (2) The KT ethical committee which is composed of three medical professors who are not belonging to the KT team to investigate and revise the process of preparation, including the soundness of donation principles; (3) Each patient with a PLD of more than the second degree genetic relatedness had to introduce the proofs (official papers or documents) of the relatedness to his PLD from the Civil Registry Office; (4) As mentioned above, each PLD accepted for donation of his kidney had to sign a consent that the donation was for free without any financial or non-financial rewards from the intended recipient or from other relatives. This consent was documented by the Real Estate Publicity Department and Documentation Office; and (5) The Egyptian High Committee of Organ Transplantation revises all these files and documents to prove the family tree and degree of relatedness between each candidate PLD and the intended recipient.

#### *Ethical approval*

This study was conducted as part of a <sup>2</sup> research project on the outcomes of LDKT performed in our center. The institutional review board number is 17200148/2017.

### *Statistical analysis*

It was performed with EasyMedStat software (version 3.21.4; www.easymedstat.com). The continuous data were presented as mean  $\pm$  SD and range. The categorical data were presented as frequency and percentage for each category. Two groups of PLDs were compared: candidate PLDs after a completed evaluation *vs.* non-candidate PLDs with a complete or incomplete evaluation. <sup>1</sup> Normality and heteroskedasticity of continuous data were assessed with the White test (or Shapiro-Wilk in multivariate analysis) and Levene's test, respectively. Continuous outcomes were compared with the unpaired Student *t*-test, Welch *t*-test, or Mann-Whitney *U* test according to the data distribution. Categorical outcomes were compared with the chi-squared or Fisher's exact test. A multivariate logistic regression was performed to assess the factors contributing to the achievement of PLD candidacy. <sup>4</sup> The data were checked for multicollinearity with the Belsley-Kuh-Welsch technique. A *P* value <0.05 was considered statistically significant.

### **RESULTS**

<sup>5</sup> A total of 302 patients were referred to our center for related LDKT during the time frame of this study. The mean age (range) was 32.0  $\pm$  11.7 (12-66) years. Of them, 44 (14.6%) patients did not have PLDs at presentation. The remaining 258 (85.4%) patients had 1-3 PLDs, constituting a total of 339 related PLDs. Eighteen (5.3%) PLDs were considered unwilling to donate a kidney as they could not confirm their willingness at the initial contact and presentation and were excluded from the study. However, the remaining 321 (94.7%) PLDs confirmed their initial willingness to donate to 254 relative patients and were included in the study (Figures 1 and 2). The mean (range) age of the PLDs was 39.7  $\pm$  10.4 (18-65) years, and they included 116 (36.1%) males and 205 (63.9%) females.

Despite the confirmed willingness, 64 of 321 PLDs (19.9%) did not start the evaluation. The causes included financial inability in 14 PLDs (21.9%), serving as reserve donors in 8



PLDs (12.5%), patient non-candidacy to KT in 13 PLDs (20.3%), patient regression from KT in 27 PLDs (42.2%), and patient death in 2 PLDs (3.1%).

The remaining 257 PLDs (80.1%) were relatives of 212 patients (83.5%) (Tables 2-4). At the different levels of evaluation and preparation for the final acceptance as LDs (Figure 2), these 257 PLDs variably passed these levels of evaluation with two main outcomes. The first outcome was the completion of the evaluation with candidacy in 74 (28.8%) PLDs. The second outcome was the failure to achieve the candidacy outcome in 183 (71.8%) PLDs (Table 3). The causes of the latter outcome were PLD exclusion in 144 PLDs (72.4%), regression from the donation decision in 18 PLDs (9%), and release after the disqualification of their potential recipients in 37 PLDs (18.6%) (Tables 3 and 4). In PLDs with candidacy for donation, and 16 PLDs (21.6%) did not commit to donation. Accordingly, only 58 (78.4%) LDs succeeded in committing to donating a kidney to their related recipients, representing 18.1% of the total 321 PLDs (Figures 1 and 2; Table 4). Single and multiple PLDs were found to be related to 165 (77.8%) and 47 (22.2%) patients, respectively. The respective percentages of achieved donations (26.7% *vs* 29.8%) were not significantly different ( $P = 0.674$ ).

In the 144 excluded PLDs, the causes of exclusion were immunological incompatibilities in 54 (37.5%) PLDs, medical abnormalities in 79 (60.4%), and financial inability in 3 (2.1%) PLDs. In addition, the exclusion was distributed per intended patient. Exclusion occurred before or after completion of the evaluation in 109 (75.7%) and 35 (24.3%) PLDs, respectively (Table 4).

A comparison was performed between patients with candidate PLDs and patients with non-candidate PLDs. Their characteristics and PLD-related distributions were not significantly different, except in the mean age, which was lower in patients with candidate PLDs ( $P = 0.041$ ). During a variable follow-up period, patients with declined PLDs mostly remained on dialysis for 6 months to 6 years (Tables 2-4).

Also, a comparison was performed between the candidate and non-candidate PLDs. Their characteristics were not significantly different, except in the degree of relatedness

to their potential recipients ( $P = 0.020$ ) and the time spent in the evaluation of PLDs. The latter was lower in patients with non-candidate PLDs ( $P < 0.001$ ) (Table 5).

A multivariate logistic regression analysis of factors influencing the candidacy of PLDs was carried out. It revealed that the on-dialysis potential recipient ( $P = 0.451$ ), younger age PLDs ( $P = 0.925$ ), male PLDs ( $P = 0.940$ ), degrees of relatedness to the recipient versus the first degree ( $P = 0.834$ ), and multiplicity of PLDs ( $P = 0.123$ ) were not significantly associated with the rate of candidacy of PLDs for LKD after completion of preparation (Table 6).

## **DISCUSSION**

The state of the art of the decline of PLDs is related to the availability of PLDs, the balance between the donors' safety and the recipient's benefit, and the achievement of LDKT as the optimal outcome of all these issues<sup>[5,6,8]</sup>. The decline of PLDs is the backbone of the failure to maintain the availability of PLDs for the majority of patients<sup>[6]</sup>. Its burden extends between and reflects on the medical and psychosocial integrities of the PLDs and their intended recipients. However, the current literature is still insufficient to resolve this problem because the rates of acceptance of LDs are still variably low<sup>[5]</sup>. Hence, the current situation mandates further study of the two main aspects of the process of evaluating PLDs. First, the root causes of the failure of high proportions of those PLDs to achieve the task of donating a kidney represent a major topic, despite the limited current literature. Many studies addressed the identification of these causes to help reduce their effects on the process of LKD<sup>[5,6,8]</sup>. Second, the fate of the intended recipients who had their PLDs lost is the other aspect that may be more critical in the process, because those potential recipients may have their all chances in KT permanently lost also<sup>[5,6,9,10]</sup>.

The availability of a related LD provides great chances for receiving KT, and it represents the only source of grafts in many countries and programs<sup>[2,9]</sup>. This fact may raise caution to try to decrease the rate of decline of PLDs in those programs to afford the needs of the increasing pool of potential recipients over time. However, the evaluation protocols for suitable LD selection remain a safeguard against violations of donor safety,

implementing a complex evaluation process<sup>[2,9,10]</sup>. According to this process, KT centers usually evaluate their LDs' acceptance and exclusion processes in the context of the principle of non-violation of the donor's safety<sup>[3,11]</sup>. Our center implements only the LDKT strategy; hence, we evaluated the rate of candidacy and acceptance of LDs, the causes of declined PLDs, and the fate of potential recipients with declined PLDs.

Although the current rate of successful candidacy of PLDs is similar to other reported values from other centers, it is relatively hard to expect the exact percentage of PLDs who ultimately succeed in committing to LKD. This uncertainty in the acceptance rates can be attributed to the variability in the assessment protocols and stages from one center to another and from one country to another<sup>[5,8]</sup>. The stages of evaluation in our center may be different from those in other centers, due to socioeconomic factors and different policies of donation<sup>[5,9]</sup>. We considered HLA-typing at the late stage of evaluation due to sociodemographic reasons. Immunological tests for HLA-typing and crossmatching are costly. However, routine and multidisciplinary other laboratory evaluations can be individualized into separate steps to catch any abnormalities in medical and laboratory workups with relatively low costs. In addition, related PLDs have higher chances of being HLA-matched with their intended recipients. On the other hand, this latter characteristic may be the reason why the mean age of the potential recipients was significantly lower than that of the PLDs. First- and second-degree relatedness between the PLDs and their potential recipients provided high proportions of parents and older sisters or brothers as PLDs for their relatives.

The efficiency of the evaluation of PLDs should consider the needs of the PLD, the intended recipient, and the qualifications of the healthcare system. The timing of the evaluation of multiple PLDs is an important issue<sup>[12]</sup>. In the current study, only the early stages of evaluation, including counseling and blood group (ABO) compatibility testing, can be carried out simultaneously due to financial causes. In addition, high proportions of PLD decline occur in the early stages of evaluation<sup>[5]</sup>. Similarly, the current results showed that more than two-thirds of PLDs were declined during the early evaluation phases.

The causes of the decline of PLDs are various and can be classified into PLD-related and patient-related causes<sup>[13]</sup>. In the current study, the major PLD-related causes included medical, immunological, and sociodemographic factors or combinations of them. ABO and HLA-incompatibilities were responsible for high percentages of excluded PLDs. Trials to expand the pool of LDs may need novel strategies, such as accepting LDs with abnormalities that are not accepted in the standard criteria for LDs. The variability of the causes of decline mandates the variability of these strategies. Hence, this practice should be implemented under strict control in LDKT programs because it may have impacts on preserving full safety issues<sup>[3,4,11]</sup>. On the same principle, such policies have not been permitted in our center protocols to avoid the violation of donor safety.

About half of the evaluated PLDs in the current study were declined due to immunological causes, including both ABO- and HLA-incompatibilities. These immunological barriers can be managed by strategies such as incompatible LDKT and paired or exchange LKD (PKD)<sup>[14]</sup>. The former strategy is certainly not acceptable due to the relatively inferior outcomes compared to the matched ABO- or HLA-compatible patients and the potential higher costs for desensitization<sup>[15]</sup>. However, PKD or kidney-sharing programs seem to be more effective for the KT programs that are based on the LDKT strategy due to their low costs and high efficiency. They are currently recommended to reduce the decline rate of PLDs, which may increase the acceptance rate of PLDs to more than 50% and provide better chances of finding high-quality donors for those who already have matched PLDs. They overcome considerable proportions of ABO- and HLA-incompatible PLDs. Unfortunately, these programs have not been established in our country so far, allowing a high rate of PLD loss. However, it has gradually become the focus of some interested researchers in the KT community<sup>[16,17]</sup>.

The PLDs could be disqualified from donation for different medical contraindications. These reasons vary from one program to another program<sup>[3,5]</sup>. In the current study, medical contraindications represented more than 60% of the causes of the decline of PLDs, similar to previously reported experiences<sup>[5]</sup>. They included several clinical forms, such as systemic diseases, infections, urolithiasis, and primary kidney diseases with

hereditary or familial patterns. These reasons may benefit from the relaxation of the standard criteria for donation, such as accepting those PLDs with mild hypertension, obesity, proteinuria, sporadic urolithiasis, or microscopic hematuria<sup>[3,18]</sup>.

Another right for PLD is autonomy, which provides him with the full capacity to preserve the ability to withdraw at any stage of preparation up to the date of surgery<sup>[19]</sup>. This right may contribute to the decline of PLDs due to withdrawal or regression from the decision to donate. In our study, 18 PLDs (7%) regressed from donation due to fear of health concerns, and 5 of them withdrew their decision after completion of the evaluation. Their potential recipients failed to find other suitable donors and remained on hemodialysis. Although it is disappointing to the potential recipients, PLD regression usually occurs in small percentages of whole PLDs. However, it warrants the help of the team to support the PLD in his decision and communicate with the potential recipient to deliver the decision<sup>[19]</sup>. Connaughton *et al*<sup>[5]</sup> reported that 15.5% of PLDs withdrew from donation during evaluation. A study by Liu *et al*<sup>[20]</sup> reported self-ranking health conditions, support in decision-making, value clarity, and conflicts in the decisions as factors of withdrawal.

For a PLD, withdrawal or being withdrawn indicates more time for finding another PLD. In our study, some patients found suitable donors after many trials among relatives. There is no doubt that this process was time-consuming, and the patients waited on dialysis for years. Also, some of them died while they were waiting for a donor. Moreover, the majority of the potential recipients are still waiting on regular dialysis or have been transplanted in other places that, mostly, may adopt the unrelated LDKT. The latter policy may predispose to such an unfavorable act of paid LKD. Hence, we preserved this policy for limited indications, such as cases of hereditary or familial primary renal diseases, including polycystic kidney disease. However, the discussion of the point of paid LKD is beyond the scope of this study.

Patient-related causes of the decline of PLDs included patient withdrawal from KT, non-candidacy, and death during preparation. We defined those PLDs as released ones because the intended recipients were disqualified. In an interview study by Pronk *et al*<sup>[21]</sup>,

patients expressed moral causes for regression from accepting related PLDs, such as reluctance to accept a kidney from close relatives and fear of being considered selfish.

The duration of PLD evaluation is variable and may be lengthy for repeating or confirmatory workups. Understanding the reasons that may prolong the evaluation may help reduce unnecessary delays<sup>[12]</sup>. The duration of evaluation in this study varied from 2 wk to 6 mo, with an average of 2.2 mo. This variation is because we considered all the PLDs with incomplete or complete evaluations.

Most of the potential recipients with declined PLDs remained on hemodialysis for variable periods ranging from 6 mo to 6 years. This means that the chances of achieving LDKT were reduced for those potential recipients when their PLDs were declined. Only 14 (6.6%) patients with declined PLDs succeeded in having LDKT in other centers, representing low chances of having LDKT similar to the results of previous studies<sup>[5]</sup>. In addition, patients with multiple PLDs did not significantly have higher chances of achieving KT. This might be attributed to the healthcare system implemented in our country, where most patients sought medical consultations in private clinics, and their PLDs had initial evaluations with their private physicians before the presentation to our center. PLDs with known systemic diseases and ABO typing can easily be excluded. In turn, this may be an explanation for the presentation of a single PLD in 77.8% of patients.

The outcomes of the current study should attract attention to the formulation of efficient plans to reduce the rates of decline of PLDs and promote LKD through the introduction of strategies such as PKD to our national program. Also, national initiatives for the education of the public, patients, and general practitioners about the advantages of LDKT and LKD may help reduce the decline of PLDs caused by the reluctance and low medical literacy of those individuals.

To the best of our knowledge, the current study is the first one from Egypt that specifically addresses the topic of the decline of PLDs among the related PLDs and recipients. This is a very important step in the development of an integrated national KT program, which has only been dependent on LKD until now. The current study may encourage other centers to conduct similar studies to provide better evidence of the

problem and formulate a plan to overcome the causes of the decline of PLDs. In addition, the aim, rationale, and outcomes of this study came in parallel to many studies from different countries<sup>[3,5,6,8,13]</sup>, which may strengthen the effect of its outcomes on the improvement of our practice and healthcare system management.

The limitations of this study include the retrospective nature of the methods. The retrospective nature may be the reason that the regression of PLDs and their recipients was not reported in detail and whether these events were due to improper counseling, sociodemographic characteristics, or the low integrity of the healthcare system. In addition, a relatively short follow-up period limited the evaluation of the long-term effect of the decline of PLDs on the fate of some intended recipients. Moreover, it was a single-center experience, which warrants further national or multi-center studies for the generalizability of these results. However, most of the available literature comes from retrospective single-center studies<sup>[3,5,8,13]</sup>.

## **CONCLUSION**

The willing, related PLDs have a mean age higher than their potential recipients due to relatedness; most of them were parents or older relatives. Also, their potential recipients had primary kidney diseases that relatively affect young people. The rate of decline of the willing, related PLDs was high, reaching about 82%. The causes could be classified as PLD-related or potential recipient-related, depending on the side of the cause. In addition, they could be differentiated into exclusion due to contraindications, release after disqualification of the potential recipients, and regression due to withdrawal of the decision by the PLDs, based on the autonomy of decision-making. PLDs exclusion was the commonest form due to medical or immunological contraindications, which were the major causes of exclusion during or after the completion of the evaluation. These high percentages of PLD decline resulted in the loss of chances of obtaining LDKT for high percentages of potential recipients who were left on dialysis for variably long periods, died, or were lost to an unknown fate. This study represents the initial scientific step in the evidence-based evaluation of the situation of LD selection and its deficits. The high

rate of decline of PLDs reported here may draw attention to implementing more research on this topic.

## **ARTICLE HIGHLIGHTS**

### ***Research background***

The evaluation protocols for living kidney donor (LD) selection are usually strict but remain a safeguard against violations of LD safety. Hence, the decline of willing potential living donors (PLDs) may occur at any stage of evaluation due to different causes, resulting in variable rates of decline of PLDs.

### ***Research motivation***

The rate of decline of willing related LDs seems to be a modifiable variable for improving LD kidney transplantation (LDKT).

### ***Research objectives***

To identify the causes of the decline of PLDs, the predictors of PLD candidacy, and the effect on achieving LDKT.

### ***Research methods***

A retrospective study was performed on willing PLDs who attended our outpatient clinic for kidney donation to their related potential recipients between October 2015 and December 2022. Two groups of PLDs were compared: candidate PLDs after a completed evaluation *vs* non-candidate PLDs with a complete or incomplete evaluation. A **1** multivariate logistic regression was performed to assess the factors contributing to the achievement of PLD candidacy.

### ***Research results***

Of 321 willing PLDs, 257 (80.1%) accessed the evaluation to variable extents for 212 potential recipients, with a mean age (range) of  $40.5 \pm 10.4$  (18-65) years. The remaining



64 (19.9%) PLDs did not access the evaluation due to serving as alternatives to essential PLDs, financial causes, and patient-related factors. Only 58 (18.1%) PLDs achieved donation, but 199 (62%) were declined. Exclusion occurred in 144 (56%) PLDs for immunological (37.5%), medical (60.4%), and financial (2.1%) causes, but regression and release occurred in 55 (17.1%) PLDs. The number of potential recipients with candidate PLDs was not significantly different from that with non-candidate PLDs, except in age ( $P = 0.041$ ), rates of completed evaluation, and exclusion of PLDs ( $P < 0.001$ ). In multivariate analysis, there were no independent factors that influenced the rate of PLD candidacy. Most patients who failed to have KT after the decline of their PLDs remained on hemodialysis for 6 mo to 6 years.

### ***Research conclusions***

Despite the availability of willing related PLDs for most potential recipients, their rate of decline was high. The causes were various, including medical or immunological contraindications, release, and regression of PLDs. Hence, the chances of high percentages of potential recipients in LDKT were reduced or lost.

### ***Research perspectives***

Trials to reduce the rate of decline of PLDs should not be at the expense of LD safety. However, revision and identification of the causes of PLD decline may help increase the chances of patients in KT, especially with the application of strategies that overcome the immunological barriers of LDKT.

## **REFERENCES**

1 **Meier-Kriesche HU**, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. *Transplantation* 2002; **74**: 1377-1381 [PMID: 12451234 DOI: 10.1097/00007890-200211270-00005]

- 2 **Simforoosh N**, Shemshaki H, Nadjafi-Semnani M, Sotoudeh M. Living related and living unrelated kidney transplantations: A systematic review and meta-analysis. *World J Transplant* 2017; **7**: 152-160 [PMID: 28507918 DOI: 10.5500/wjt.v7.i2.152]
- 3 **Kim IK**, Tan JC, Lapasia J, Elihu A, Busque S, Melcher ML. Incidental kidney stones: a single center experience with kidney donor selection. *Clin Transplant* 2012; **26**: 558-563 [PMID: 22168332 DOI: 10.1111/j.1399-0012.2011.01567.x]
- 4 **Gambaro G**, Zaza G, Citterio F, Naticchia A, Ferraro PM. Living kidney donation from people at risk of nephrolithiasis, with a focus on the genetic forms. *Urolithiasis* 2019; **47**: 115-123 [PMID: 30470867 DOI: 10.1007/s00240-018-1092-4]
- 5 **Connaughton DM**, Harmon G, Cooney A, Williams Y, O'Regan J, O'Neill D, Cunningham P, Counihan A, O'Kelly P, McHale S, Denton M, O'Seaghda CM, Magee C, Conlon P, Little D, Keogan M, de Freitas DG. The Irish living kidney donor program - why potential donors do not proceed to live kidney donation? *Clin Transplant* 2016; **30**: 17-25 [PMID: 26426147 DOI: 10.1111/ctr.12641]
- 6 **Arunachalam C**, Garrues M, Biggins F, Woywodt A, Ahmed A. Assessment of living kidney donors and adherence to national live donor guidelines in the UK. *Nephrol Dial Transplant* 2013; **28**: 1952-1960 [PMID: 23658249 DOI: 10.1093/ndt/gft096]
- 7 **Skrunes R**, Svarstad E, Reisæter AV, Vikse BE. Familial clustering of ESRD in the Norwegian population. *Clin J Am Soc Nephrol* 2014; **9**: 1692-1700 [PMID: 25092600 DOI: 10.2215/CJN.01680214]
- 8 **Lapasias JB**, Kong SY, Busque S, Scandling JD, Chertow GM, Tan JC. Living donor evaluation and exclusion: the Stanford experience. *Clin Transplant* 2011; **25**: 697-704 [PMID: 21044160 DOI: 10.1111/j.1399-0012.2010.01336.x]
- 9 **Rashad H**, Fahmy A, Eissa A, Elsherbiny A. Committee XII: Renal Transplantation. In: Mourad S, Shalaby M, El Halaby, Morsy A, Elgamasy AN, Hamouda H. Egyptian Urological Guidelines Book. [cited 1 April 2023]. Available from: <http://eug-eg.net/>
- 10 **Gadelkareem RA**, Abdelgawad AM, Reda A, Azoz NM, Zarzour MA, Mohammed N, Hammouda HM, Khalil M. Preemptive living donor kidney transplantation: Access, fate,

and review of the status in Egypt. *World J Nephrol* 2023; **12**: 40-55 [PMID: 37476008 DOI: 10.5527/wjn.v12.i3.40]

11 **Romagnoli J**, Salerno MP, Mamode N, Calia R, Spagnoletti G, Bianchi V, Maresca M, Piccirillo N, Putzulu R, Piselli P, Cola E, Zini G, Citterio F. Expanding the Living Donor Pool "Second Act": Laparoscopic Donor Nephrectomy and ABO-Incompatible Kidney Transplantation Improve Donor Recruitment. *Transplant Proc* 2015; **47**: 2126-2129 [PMID: 26361659 DOI: 10.1016/j.transproceed.2014.11.071]

12 **Habbous S**, Arnold J, Begen MA, Boudville N, Cooper M, Dipchand C, Dixon SN, Feldman LS, Goździk D, Karpinski M, Klarenbach S, Knoll GA, Lam NN, Lentine KL, Lok C, McArthur E, McKenzie S, Miller M, Monroy-Cuadros M, Nguan C, Prasad GVR, Przech S, Sarma S, Segev DL, Storsley L, Garg AX; Donor Nephrectomy Outcomes Research (DONOR) Network. Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies. *Am J Kidney Dis* 2018; **72**: 483-498 [PMID: 29580662 DOI: 10.1053/j.ajkd.2018.01.036]

13 **AlBugami MM**, AlOtaibe FE, Boqari D, AlAbadi AM, Hamawi K, Bel'eed-Akkari K. Why Potential Living Kidney Donors Do Not Proceed for Donation: A Single-Center Experience. *Transplant Proc* 2019; **51**: 504-508 [PMID: 30879577 DOI: 10.1016/j.transproceed.2019.01.008]

14 **Kher V**, Jha PK. Paired kidney exchange transplantation - pushing the boundaries. *Transpl Int* 2020; **33**: 975-984 [PMID: 32634850 DOI: 10.1111/tri.13693]

15 **de Weerd AE**, Betjes MGH. ABO-Incompatible Kidney Transplant Outcomes: A Meta-Analysis. *Clin J Am Soc Nephrol* 2018; **13**: 1234-1243 [PMID: 30012630 DOI: 10.2215/CJN.00540118]

16 **Elrggal ME**, Tawfik M, Gawad MA, Sheasha HA. Kidney paired donation program, a national solution against commercial transplantation? *J Egypt Soc Nephrol Transplant* 2018; **18**: 6-10 [DOI: 10.4103/jesnt.jesnt\_1\_18]

17 **Hassaballa MA**. Kidney Paired Donation. *Exp Clin Transplant* 2022; **20**: 59-61 [PMID: 36018023 DOI: 10.6002/ect.DonorSymp.2022.O2]

18 **Young A**, Storsley L, Garg AX, Treleaven D, Nguan CY, Cuerden MS, Karpinski M. Health outcomes for living kidney donors with isolated medical abnormalities: a systematic review. *Am J Transplant* 2008; **8**: 1878-1890 [PMID: 18671676 DOI: 10.1111/j.1600-6143.2008.02339.x]

19 **Grossi AA**, Sever MS, Hellemans R, Mariat C, Crespo M, Watschinger B, Peruzzi L, Demir E, Velioglu A, Gandolfini I, Oniscu GC, Hilbrands L, Mjoen G. The 3-Step Model of informed consent for living kidney donation: a proposal on behalf of the DESCaRTES Working Group of the European Renal Association. *Nephrol Dial Transplant* 2023; **38**: 1613-1622 [PMID: 36702535 DOI: 10.1093/ndt/gfad022]

20 **Liu KL**, Wang HH, Hsieh CY, Huang XY, Lin CT, Lin KJ, Chiang YJ, Chien CH. Kidney Donation Withdrawal and Related Factors Among the Potential Donors of Living Kidney Transplant. *Transplant Proc* 2020; **52**: 73-77 [PMID: 31901327 DOI: 10.1016/j.transproceed.2019.11.018]

21 **Pronk MC**, Slaats D, Zuidema WC, Hilhorst MT, Dor FJMF, Betjes M, Weimar W, van de Wetering J, Massey EK. "What if this is my chance to save my life?" A semistructured interview study on the motives and experiences of end-stage renal disease patients who engaged in public solicitation of a living kidney donor. *Transpl Int* 2018; **31**: 318-331

## **Figure Legends**

**Figure 1 A flowchart of the potential living kidney donors and their intended recipients showing the levels of decline of the potential donors from the stage of access to the kidney transplantation center to the achievement of kidney transplantation.**

PLD: Protentional living donor.

**Figure 2 A diagram of the different phases of the evaluation of the potential living kidney donors, showing the essential workups, percentages of declined donors, and**

**causes of decline in each phase.** PLD: Protentional living donor; KT: Kidney transplantation; HLA: Human leukocytic antigen; PRA: DSA:

**Table 1 Definitions of terms used to describe the living donors at different stages of kidney donation; access, counseling, evaluation, acceptance, candidacy and donation with kidney transplantation of related intended patients**

<b>Term</b>	<b>Definition</b>
PLD	An individual who confirmed his willingness to donate a kidney to an intended patient at the initial counseling settings and was ready to start the evaluation for kidney donation, regardless of the evaluation started or not
Related PLD	PLD who had a relative intended patient with end-stage renal disease up to the 4 <sup>th</sup> degree of genetical relatedness. Regardless of their genetical relatedness, the wives and husbands are considered related
Excluded PLD	PLD who was disqualified as a kidney donor and excluded from the process of kidney donation by medical team due to causes that disqualify his candidacy to donate a kidney, such as the medical, immunological, or financial causes
Regressed PLD	PLD who withdrew his decision of kidney donation at any stage after an initial confirmation of the donation decision and before the operation
Released PLD <sup>1</sup>	PLD who was still willing and completed or was still continuing the evaluation, but his related intended patient was withdrawn from KT preparation due to any cause
Candidate PLD	PLD who completed all the steps of evaluation and was finally accepted by the medical team for kidney donation, regardless of his later on regression or release from donation
Accepted PLD	PLD who completed the evaluation without exclusion from kidney donation and was accepted for donation without release or regression from his willingness

LD                      PLD becomes a LD when he succeeds in donating a kidney to his intended patient, which also means KT was achieved

Relatedness        First degree: Father, mother, son, daughter, wife, and degrees        and husband; second degree: Brother, sister, grandfather, forms<sup>2</sup>                      grandmother, grandson, and granddaughter; third degree: Uncle, aunt; and fourth degree: Cousins

---

<sup>1</sup>In this study, release of the donor means that the donor became free from any commitment to donating a kidney because his relative intended patient was excluded, regressed, or died. In addition, the donor would not be allocated to another patient, as he/she was willing to donate to his intended relative only.

<sup>2</sup>Husband-wife couples were processed as first-degree related potential living donors when donations were planned between each couple. However, they may be genetically related or unrelated, relative to their pre-marriage relatedness.

KT: Kidney transplantation; LD: Living donor; PLD: Potential living donor.

**Table 2 Demographic and clinical characteristics of patients and related potential living donors presented as total patients ( $n = 212$ ) and as a comparison between patients with candidate ( $n = 74$ ) and patients with non-candidate ( $n = 138$ ) potential living donors**

Characteristics	Total patients ( $n = 212$ )	Patients with candidate PLDs ( $n = 74$ )	Patients with non-candidate PLDs ( $n = 138$ )	<i>P</i> value
	Mean $\pm$ SD (percentage)	Mean $\pm$ SD (percentage)	Mean $\pm$ SD (percentage)	
Mean age (yr)	31.2 $\pm$ 10.6 (13-66)	29.1 $\pm$ 9.6 (13-57)	32.9 $\pm$ 12.0 (14-66)	0.041
Sex ( $n = 212$ )				
Males	173 (81.6%)	67 (90.5%)	106 (76.8%)	0.087
Females	39 (18.4%)	7 (9.5%)	32 (23.2%)	
Status of dialysis at presentation ( $n = 212$ )				
Preemptive	19 (9.0%)	5 (6.8%)	14 (10.1%)	0.462
On regular hemodialysis	193 (91.0%)	69 (93.2%)	124 (89.9%)	
Primary kidney disease ( $n = 212$ )				
Unknown	167 (78.8%)	56 (75.7%)	111 (80.4%)	0.088
Systemic disease	14 (6.6%)	3 (2.7%)	11 (8.0%)	
Glomerulonephritis	6 (2.8%)	3 (4.0%)	3 (2.2%)	
Hereditary renal disease	5 (3.8%)	2 (2.7%)	3 (2.2%)	
Obstructive uropathy	11 (5.2%)	8 (10.8%)	3 (2.2%)	
Urolithiasis	9 (4.2%)	2 (2.7%)	7 (5.1%)	
Categories of primary kidney disease ( $n = 212$ )				
Unknown	167 (78.8%)	56 (75.7%)	111 (80.4%)	0.154



Systemic disease	14 (6.6%)	3 (4.0%)	11 (8.0%)	
Local (renal/urinary)	31 (14.6%)	15 (20.3%)	16 (11.6%)	
Patients per number of PLDs ( <i>n</i> = 212)				
Patients with one PLD	165 (77.8%)	53 (71.6%)	112 (81.2%)	0.265
Patients with two PLDs	39 (18.4%)	17 (23.0%)	22 (15.9%)	
Patients with three PLDs	8 (3.8%)	4 (5.4%)	4 (2.9%)	

---

PLD: Potential living donor.

**Table 3 Patients distributed per extent and outcome of evaluation of their potential living donors presented as total patients ( $n = 212$ ) and as a comparison between patients with candidate ( $n = 74$ ) and patients with non-candidate ( $n = 138$ ) potential living donors.**

Characteristics	Total	Patients	Patients	P	
	patients ( $n = 212$ )	with candidate PLDs ( $n = 74$ )	with non-candidate PLDs ( $n = 138$ )		
	Mean	$\pm$ SD	(range)/number		
<b>(percentage)</b>					
Patients per extent of evaluation of their PLDs <sup>1</sup> ( $n = 212$ )					
Completed 1	71 (33.5%)	54 (73%)	17 (12.3%)	< 0.001	
Completed 1/incomplete 1	15 (7.1%)	7 (9.5%)	8 (5.8%)		
Completed 1/incomplete 2	2 (0.9%)	2 (2.7%)	0 (0%)		
Completed 1/not evaluated 1	7 (3.3%)	6 (8.1%)	1 (0.7%)		
Completed 2	3 (1.4%)	3 (4.1%)	0 (0%)		
Completed 2/incomplete 1	1 (0.5%)	0 (0%)	1 (0.7%)		
Completed 3	2 (0.9%)	2 (2.7%)	0 (0%)		
Incomplete 1	94 (44.3%)	0 (0%)	94 (68.1%)		
Incomplete 1/not evaluated 1	1 (0.5%)	0 (0%)	1 (0.7%)		
Incomplete 1/not evaluated 2	1 (0.5%)	0 (0%)	1 (0.7%)		
Incomplete 2	13 (6.1%)	0 (0%)	13 (9.4%)		
Incomplete 3	2 (0.9%)	0 (0%)	2 (1.5%)		
Patients per acceptance of their PLDs <sup>1</sup> ( $n = 212$ )					
Accepted 1	44 (20.6%)	44 (59.5%)	0 (0%)		< 0.001

Accepted 1/excluded 1	8 (3.8%)	8 (10.8%)	0 (0%)
Accepted 1/excluded 2	2 (0.9%)	2 (2.7%)	0 (0%)
Accepted 1/not evaluated 1	4 (1.9%)	4 (5.4%)	0 (0%)
Excluded 1	81 (38.2%)	0 (0%)	81 (0%)
Excluded 2	14 (6.6%)	0 (0%)	14 (10.1%)
Excluded 3	2 (0.9%)	0 (0%)	2 (1.5%)
Excluded 1/released 1	5 (2.4%)	1 (1.4%)	4 (2.9%)
Excluded 1/regressed 1	3 (1.4%)	1 (1.4%)	2 (1.5%)
Excluded 1/not evaluated 1	2 (0.9%)	0 (0%)	2 (1.5%)
Excluded 1/not evaluated 2	1 (0.5%)	0 (0%)	1 (0.7%)
Excluded 2/released 1	2 (0.9%)	1 (1.4%)	1 (0.7%)
Excluded 2/regressed 1	1 (0.5%)	1 (1.4%)	0 (0%)
Released 1	28 (13.2%)	7 (9.5%)	21 (15.2%)
Released 1/not evaluated 1	2 (0.9%)	2 (2.7%)	0 (0%)
Regressed 1	12 (5.7%)	3 (4.1%)	9 (6.5%)
Regressed 2	1 (0.5%)	0 (0%)	1 (0.7%)

<sup>†</sup>The numbers here refer to the number of potential living donors who had this character. In addition, the included 10 potential donors who were not evaluated, and they presented here as parts of combined donors to the same patients with evaluated donors.

PLD: Potential living donor.

**Table 4 Patients distributed per characteristics of exclusion of their potential living donors presented as total patients ( $n = 212$ ) and as a comparison between patients with candidate ( $n = 74$ ) and patients with non-candidate ( $n = 138$ ) potential living donors.**

Characteristics	Total	Patients	Patients	<i>P</i> value
	patients ( $n = 212$ )	with candidate PLDs ( $n = 74$ )	with non-candidate PLDs ( $n = 138$ )	
	Mean	± SD	(range)/number	
<hr/>				
Patients per number of excluded PLDs ( $n = 121$ )				
Patients with one excluded PLD	100 (82.6%)	10 (71.4%)	90 (84.1%)	0.764
Patients with two excluded PLDs	19 (15.7%)	4 (28.6%)	15 (14.0%)	
Patients with three excluded PLDs	2 (1.7%)	0 (0%)	2 (1.9%)	
Patients per causes of exclusion of their PLDs ( $n = 121$ ) <sup>1</sup>				
Combined immunological and medical causes	14 (11.6%)	3 (21.4%)	11 (10.3%)	0.680
HLA-incompatibility	24 (19.8%)	3 (21.4%)	21 (19.6%)	
ABO-incompatibility	20 (16.5%)	1 (7.1%)	19 (17.8%)	
ABO and HLA-incompatibility	2 (1.7%)	0 (0%)	2 (1.9%)	
Age	8 (6.6%)	0 (0%)	8 (7.5%)	
Diabetes mellitus	4 (3.3%)	0 (0%)	4 (3.7%)	
HCV positive	5 (4.1%)	2 (14.3%)	3 (2.8%)	
Hypertension	11 (9.1%)	4 (28.6%)	7 (6.5%)	
Leprosy	1 (0.8%)	0 (0%)	1 (0.9%)	

Low GFR	4 (3.3%)	1 (7.1%)	3 (2.8%)	
High potential recurrence of primary kidney disease	6 (5.0%)	0 (0%)	6 (5.6%)	
Proteinuria	12 (9.9%)	0 (0%)	12 (11.2%)	
Psoriasis	1 (0.8%)	0 (0%)	1 (0.9%)	
Rheumatoid arthritis	1 (0.8%)	0 (0%)	1 (0.9%)	
Urolithiasis	5 (4.1%)	0 (0%)	5 (4.7%)	
Financial causes	3 (2.5%)	0 (0%)	3 (2.8%)	
Patients per main category of causes of exclusion of their PLDs ( <i>n</i> = 121)				
Combined immunological and medical causes	14 (11.6%)	3 (21.4%)	11 (10.3%)	0.866
Immunologic mismatches	46 (38%)	4 (28.6%)	42 (39.3%)	
Medical causes	58 (47.9%)	7 (50.0%)	51 (47.7%)	
Financial causes	3 (2.5%)	0 (0%)	3 (2.8%)	
Patients per timing of PLDs regression ( <i>n</i> = 18)				
During evaluation	13 (72.2%)	0 (0%)	13 (100.0%)	NS
After evaluation	5 (27.8%)	5 (100.0%)	0 (0%)	
Patients per cause of release of PLDs ( <i>n</i> = 37)				
Patient death	4 (10.8%)	3 (27.3%)	1 (3.9%)	0.186
Patient regression	22 (59.5%)	6 (54.5%)	16 (61.5%)	
Patient non-candidacy	11 (29.7%)	2 (18.2%)	9 (34.6%)	
Patients per timing of release of PLDs ( <i>n</i> = 37)				
During evaluation	26 (70.3%)	0 (0%)	26 (100.0%)	NS
After evaluation	11 (29.7%)	11 (100.0%)	0 (0%)	
Fate of patients with evaluated PLDs ( <i>n</i> = 212)				

Transplantation in our center	58 (27.4%)	58 (78.4%)	0 (0%)	NS
Transplantation in another center	14 (6.6%)	1 (1.4%)	13 (9.4%)	0.024
On hemodialysis	122 (57.6%)	12 (16.2%)	110 (79.7%)	< 0.001
Death	9 (4.2%)	3 (4.1%)	6 (4.4%)	0.920
Unknown	9 (4.2%)	0 (0%)	9 (6.5%)	0.024

<sup>1</sup>Regarding the exclusion due to anatomical abnormalities, they included ectopic pelvic kidney, solitary kidney, and hypoplastic kidney in three patients. They were included in donors with a low split glomerular filtration rate. However, kidneys with unilateral simple cysts in two patients and three renal arteries in other two patients were not the cause of exclusion. In the former, the cysts were treated by marsupialization after perfusion and before implantation in the recipients. In the latter, the contralateral kidneys were donated.

PLD: Potential living donor; HLA: Human leukocytic antigen; HCV: Hepatitis C virus; NS: Not significant.

**Table 5 Characteristics of potential living donors presented as total (*n* = 257) and as a comparison between the candidate (*n* = 74) and non-candidate (*n* = 183) groups of donors**

Characteristics	Total PLDs ( <i>n</i> = 257)	Candidate PLDs ( <i>n</i> = 74)	Non-candidate PLDs ( <i>n</i> = 183)	<i>P</i> value
	Mean ± SD (range)/number (percentage)			
Mean age (yr)	40.5 ± 10.4 (18-65)	41.0 ± 10.5 (21-60)	40.4 ± 10.5 (18-65)	0.498
Sex				
Women	169 (65.8%)	49 (66.2%)	120 (65.6%)	> 0.999
Men	88 (34.2%)	25 (33.8%)	63 (34.4%)	
Form of relatedness <sup>1</sup>				
Aunt	4 (1.6%)	4 (5.4%)	0 (0%)	0.286
Brother	51 (19.8%)	14 (18.9%)	37 (20.2%)	
Cousin	4 (1.6%)	0 (0%)	4 (2.2%)	
Daughter	4 (1.6%)	1 (1.4%)	3 (1.6%)	
Father	23 (8.9%)	7 (9.5%)	16 (8.7%)	
Husband	6 (2.3%)	2 (2.7%)	4 (2.2%)	
Mother	76 (29.6%)	23 (31.1%)	53 (29%)	
Nephew	1 (0.4%)	0 (0%)	1 (0.6%)	
Sister	53 (20.6%)	13 (17.6%)	40 (21.9%)	
Son	4 (1.6%)	1 (1.4%)	3 (1.6%)	
Uncle	1 (0.4%)	1 (1.4%)	0 (0%)	
Wife	30 (11.7%)	8 (10.8%)	22 (12.0%)	
Degree of relatedness				
First	143 (55.6%)	42 (56.8%)	101 (55.2%)	0.020
Second	104 (40.5%)	27 (36.5%)	77 (42.1%)	
Third	6 (2.3%)	5 (6.8%)	1 (0.6%)	
Fourth	4 (1.6%)	0 (0%)	4 (2.2%)	

Extent of evaluation				
Complete	109 (42.4%)	74 (100.0%)	35 (19.1%)	NS
Incomplete	148 (57.6%)	0 (0%)	148 (80.9%)	
Fate of PLDs				
Donated	58 (22.6%)	58 (78.4%)	0 (0%)	NS
Excluded	144 (56.0%)	0 (0%)	144 (78.7%)	NS
Regressed <sup>2</sup>	18 (7.0%)	5 (6.8%)	13 (31.6%)	
During evaluation	13 (72.2%)	0 (0%)	13 (100.0%)	NS
After evaluation	5 (27.8%)	5 (100%)	0 (0%)	
Released	37 (14.4%)	11 (14.9%)	26 (68.4%)	
Causes of donor release				
Patient death	4 (10.8%)	3 (27.3%)	1 (3.9%)	0.186
Patient regression	22 (59.5%)	6 (54.5%)	16 (61.5%)	
Patient non-candidacy	11 (29.7%)	2 (18.2%)	9 (34.6%)	
Timing of PLDs release				
During evaluation	26 (70.3%)	0 (0%)	26 (100.0%)	NS
After evaluation	11 (29.7%)	11 (100.0%)	0 (0%)	
Time spent in PLDs evaluation (m)	2.2 ± 1.5 (0.5-6.0)	4.0 ± 0.9 (1-6)	1.5 ± 1.2 (0.5-5.0)	< 0.001

<sup>1</sup>Among the 6 husbands and 30 wives potential living donors (PLDs), only 13 of them were genetically related PLDs to their intended recipients in their husband-wife couples (due to consanguineous marriage).

<sup>2</sup>The reason of regression was the fear of health drawbacks from donation in all PLDs.

NS: Not significant; PLDs: Potential living donor.



**Table 6 Multivariate logistic regression of the potential variables influencing the candidacy of potential living donors with a completed preparation**

<b>Variables</b>	<b>Modality</b>	<b>Odds ratio</b>	<b>P value</b>
Dialysis status	Preemptive versus on dialysis	0.66 (0.23-1.94)	0.451
Number of potential donors	Single versus multiple	1.69 (0.87-3.28)	0.123
Donor age	Increasing age	1.0 (0.97-1.03)	0.925
Donor gender	Men versus women	1.02 (0.55-1.92)	0.940
Relatedness degree	First versus more than first	1.07 (0.55-2.1)	0.834

# 3%

SIMILARITY INDEX

---

### PRIMARY SOURCES

---

1	<a href="http://www.ncbi.nlm.nih.gov">www.ncbi.nlm.nih.gov</a> Internet	106 words — 1%
2	Rabea Ahmed Gadelkareem, Amr Mostafa Abdelgawad, Ahmed Reda, Nashwa Mostafa Azoz et al. "Preemptive living donor kidney transplantation: Access, fate, and review of the status in Egypt", World Journal of Nephrology, 2023 Crossref	43 words — 1%
3	<a href="http://www.f6publishing.com">www.f6publishing.com</a> Internet	33 words — < 1%
4	<a href="http://ccforum.biomedcentral.com">ccforum.biomedcentral.com</a> Internet	20 words — < 1%
5	<a href="http://www.researchgate.net">www.researchgate.net</a> Internet	20 words — < 1%

---

EXCLUDE QUOTES ON

EXCLUDE SOURCES < 15 WORDS

EXCLUDE BIBLIOGRAPHY ON

EXCLUDE MATCHES < 10 WORDS